- In December 2023, Padagis, a pharmaceutical company, received U.S. FDA approval to market Podofilox Gel, the first generic version of Condylox Gel 0.5%, in the United States. This topical antimitotic medication is used for treating anogenital warts, including external genital and perianal warts. The approval marks a significant step in providing a more affordable treatment option for patients in the U.S
- In January 2023, Verrica Pharmaceuticals announced receiving the meeting minutes from its Type C meeting with the FDA, held on November 6, 2023. The meeting focused on discussing the Phase 3 clinical development plan for YCANTH as a treatment for common warts. Verrica is optimistic that the meeting helped align on the pivotal Phase 3 study design, which is essential for expanding YCANTH’s indication, currently approved for molluscum contagiosum, to include common warts, pending further clinical trials
